Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Retrievable vena caval filters with anticoagulation vs anticoagulation Filter‐related complications (up to 232 days) · participants who sustained multiple traumatic injuriesa Vena caval filters for the prevention of pulmonary embolism (2020) · Cochrane | no estimate extracted | 1 study · 240 participants | Moderate |
Atherectomy vs balloon angioplasty Primary patency ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 1.06 [0.94, 1.2] | 3 studies · 186 participants | Very low |
Atherectomy vs balloon angioplasty with primary stenting Mortality ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 0.38 [0.04, 3.23] | 1 study · 155 participants | Very low |
Atherectomy vs balloon angioplasty with primary stenting Fatal and non‐fatal cardiovascular events ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 0.38 [0.04, 3.23] | 1 study · 155 participants | Very low |
Atherectomy vs balloon angioplasty with primary stenting TVR ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 2.27 [0.95, 5.46] | 1 study · 155 participants | Very low |
Atherectomy vs balloon angioplasty with primary stenting TVR ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 2.05 [0.96, 4.37] | 1 study · 155 participants | Very low |
Atherectomy vs balloon angioplasty with primary stenting Complication rates ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 7.04 [0.8, 62.23] | 1 study · 155 participants | Very low |
Atherectomy vs balloon angioplasty Primary patency ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 1.2 [0.78, 1.84] | 2 studies · 149 participants | Very low |
Atherectomy vs balloon angioplasty Mortality ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 0.5 [0.1, 2.66] | 3 studies · 210 participants | Very low |
Atherectomy vs balloon angioplasty Fatal and non‐fatal cardiovascular events ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | no estimate extracted | 2 studies · 160 participants | Very low |
Atherectomy vs balloon angioplasty TVR ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 0.51 [0.06, 4.42] | 2 studies · 136 participants | Very low |
Atherectomy vs balloon angioplasty TVR ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 0.59 [0.25, 1.42] | 3 studies · 176 participants | Very low |
Atherectomy vs balloon angioplasty Complication rates ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | RR 0.69 [0.28, 1.68] | 6 studies · 387 participants | Very low |
Atherectomy vs balloon angioplasty with primary stenting Primary patency ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Atherectomy vs balloon angioplasty with primary stenting Primary patency ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Angioplasty vs primary stenting Technical success (immediate) · patients with symptomatic Iliac artery lesions Angioplasty versus stenting for iliac artery lesions (2020) · Cochrane | no estimate extracted | 2 studies · 391 participants | Low |
Angioplasty vs primary stenting Incidence of complications (immediate) · patients with symptomatic Iliac artery lesions Angioplasty versus stenting for iliac artery lesions (2020) · Cochrane | no estimate extracted | 2 studies · 391 participants | Low |
Angioplasty vs primary stenting Improvement in the stage of PAD according to Rutherford's criteria (one year) · patients with symptomatic Iliac artery lesions Angioplasty versus stenting for iliac artery lesions (2020) · Cochrane | OR 1.03 [0.47, 2.27] | 1 study · 157 participants | Low |
Angioplasty vs primary stenting Primary patency (two years) · patients with symptomatic Iliac artery lesions Angioplasty versus stenting for iliac artery lesions (2020) · Cochrane | OR 1.6 [0.34, 7.44] | 1 study · 57 participants | Low |
Angioplasty vs primary stenting Reinterventions (six to eight years) · patients with symptomatic Iliac artery lesions Angioplasty versus stenting for iliac artery lesions (2020) · Cochrane | OR 1.22 [0.67, 2.23] | 1 study · 279 participants | Low |
Angioplasty vs primary stenting Resolution of symptoms and signs (one year) · patients with symptomatic Iliac artery lesions Angioplasty versus stenting for iliac artery lesions (2020) · Cochrane | OR 1.14 [0.65, 2] | 1 study · 219 participants | Low |
Angioplasty vs primary stenting Improvement in walking distance as reported by the patient · patients with symptomatic Iliac artery lesions Angioplasty versus stenting for iliac artery lesions (2020) · Cochrane | no estimate extracted | NR | No studies |
DOAC vs placebo Symptomatic VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.43 [0.18, 1.06] | 3 studies · 1526 participants | Low |
Low‐molecular‐weight heparin vs no thromboprophylaxis Symptomatic PE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.6 [0.42, 0.88] | 8 studies · 5324 participants | Moderate |
Low‐molecular‐weight heparin vs no thromboprophylaxis Symptomatic DVT · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.48 [0.35, 0.67] | 9 studies · 5408 participants | High |
Low‐molecular‐weight heparin vs no thromboprophylaxis Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.57 [0.46, 0.71] | 10 studies · 5743 participants | High |
Low‐molecular‐weight heparin vs no thromboprophylaxis 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.94 [0.83, 1.07] | 9 studies · 2681 participants | Low |
Low‐molecular‐weight heparin vs no thromboprophylaxis Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 3.4 [1.2, 9.63] | 4 studies · 3105 participants | Moderate |
Low‐molecular‐weight heparin vs with active control (1) Symptomatic VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 2.89 [0.12, 66.75] | 1 study · 51 participants | Low |
Low‐molecular‐weight heparin vs with active control (1) Major bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs with active control (1) Symptomatic PE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 2.89 [0.12, 66.75] | NR | Ungraded |
Low‐molecular‐weight heparin vs with active control (1) Symptomatic DVT · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs with active control (1) Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 4.81 [0.24, 95.58] | NR | Ungraded |
DOAC vs placebo Major bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 1.74 [0.82, 3.68] | 3 studies · 1494 participants | Moderate |
Low‐molecular‐weight heparin vs with active control (1) 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs with active control (1) Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (2) Symptomatic VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.51 [0.22, 1.17] | 2 studies · 781 participants | Moderate |
Low‐molecular‐weight heparin vs active control (2) Major bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.14 [0.01, 2.76] | 2 studies · 781 participants | Low |
Low‐molecular‐weight heparin vs active control (2) Symptomatic PE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.13 [0.02, 1.03] | 2 studies · 781 participants | Moderate |
Low‐molecular‐weight heparin vs active control (2) Symptomatic DVT · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.81 [0.32, 2.04] | 2 studies · 781 participants | Moderate |
Low‐molecular‐weight heparin vs active control (2) Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (2) 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (2) Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (3) Symptomatic VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.33 [0.14, 0.83] | 1 study · 439 participants | High |
DOAC vs placebo Symptomatic PE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.38 [0.1, 1.47] | 3 studies · 1526 participants | Low |
Low‐molecular‐weight heparin vs active control (3) Major bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (3) Symptomatic PE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.11 [0.01, 2.06] | 1 study · 439 participants | Low |
Low‐molecular‐weight heparin vs active control (3) Symptomatic DVT · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | RR 0.43 [0.17, 1.1] | 1 study · 439 participants | Moderate |
Low‐molecular‐weight heparin vs active control (3) Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (3) 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |